| Literature DB >> 34434228 |
Renata Markiewicz1, Agnieszka Markiewicz-Gospodarek2, Beata Dobrowolska3, Bartosz Łoza4.
Abstract
Objectives: The aim of this study was to use neurofeedback (NF) training as the add-on therapy in patients with schizophrenia to improve their clinical, cognitive, and psychosocial condition. The study, thanks to the monitoring of various conditions, quantitative electroencephalogram (QEEG) and brain-derived neurotrophic factor (BDNF), was supposed to give an insight into mechanisms underlying NF training results.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34434228 PMCID: PMC8380506 DOI: 10.1155/2021/4488664
Source DB: PubMed Journal: Neural Plast ISSN: 1687-5443 Impact factor: 3.599
Baseline and final results of combined NF/standard rehabilitation versus standard rehabilitation.
| Variable | Group | Baseline | Final | Difference absolute | Difference significance | Confidence level | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| M | SD | M | SD |
|
| −95% | +95% | |||
| PANSS-POS | NF | 9.06 | 2.04 | 7.50 | 2.23 | 1.56 | 10.719 |
| −1.86 | −1.25 |
| R | 9.28 | 2.01 | 8.24 | 2.01 | 1.04 | 6.186 |
| 0.69 | 1.39 | |
|
| ||||||||||
| PANSS-NEG | NF | 13.94 | 3.92 | 11.83 | 4.48 | 2.11 | 8.304 |
| −2.65 | −1.57 |
| R | 15.16 | 3.51 | 14.08 | 4.47 | 1.08 | 2.596 |
| 0.22 | 1.94 | |
|
| ||||||||||
| PANSS-GEN | NF | 24.83 | 3.35 | 22.61 | 3.71 | 2.22 | 10.736 |
| −2.66 | −1.79 |
| R | 27.44 | 3.31 | 25.88 | 4.20 | 1.56 | 2.742 |
| 0.39 | 2.73 | |
|
| ||||||||||
| PANSS-TOT | NF | 47.83 | 8.49 | 41.94 | 9.64 | 5.89 | 11.834 |
| −6.94 | −4.84 |
| R | 51.92 | 7.22 | 48.20 | 9.36 | 3.72 | 3.375 |
| 1.45 | 6.00 | |
|
| ||||||||||
| CTT-1 | NF | 57.19 | 26.16 | 49.31 | 24.92 | 7.88 | 1.865 | 0.082 | -16.88 | 1.13 |
| R | 59.50 | 24.00 | 54.29 | 19.74 | 5.21 | 1.861 | 0.076 | -0.58 | 11.00 | |
|
| ||||||||||
| CTT-2 | NF | 121.50 | 55.62 | 109.06 | 42.44 | 12.44 | 1.535 | 0.146 | -29.71 | 4.83 |
| R | 120.58 | 37.64 | 110.33 | 32.59 | 10.25 | 1.725 | 0.098 | -2.04 | 22.54 | |
|
| ||||||||||
| d2. %B (errors) | NF | 10.70 | 11.09 | 8.71 | 10.33 | 1.99 | 0.741 | 0.471 | −7.74 | 3.77 |
| R | 9.01 | 10.89 | 6.25 | 7.01 | 2.76 | 2.107 |
| 0.05 | 5.47 | |
|
| ||||||||||
| d2. ZK (ability to concentrate) | NF | 99.06 | 44.59 | 105.94 | 47.66 | 6.88 | −0.985 | 0.340 | −8.00 | 21.75 |
| R | 107.42 | 46.69 | 117.88 | 35.71 | 10.46 | −2.078 |
| −20.87 | −0.05 | |
|
| ||||||||||
| BCIS A (self-reflectiveness) | NF | 22.72 | 4.80 | 25.72 | 3.14 | 3.00 | −3.170 |
| −5.00 | −1.00 |
| R | 21.15 | 4.47 | 22.12 | 4.96 | 0.96 | −0.911 | 0.371 | −3.14 | 1.21 | |
|
| ||||||||||
| BCISS A-B (composite index) | NF | 8.78 | 5.35 | 12.22 | 3.17 | 3.44 | −2.946 |
| −5.91 | −0.98 |
| R | 6.38 | 4.83 | 7.35 | 5.12 | 0.96 | −1.000 | 0.327 | −2.94 | 1.02 | |
|
| ||||||||||
| AIS (illness acceptance) | NF | 22.67 | 8.95 | 26.44 | 6.46 | 3.78 | −2.547 |
| 0.65 | 6.91 |
| R | 25.96 | 8.77 | 25.00 | 7.83 | 0.96 | 0.557 | 0.583 | −2.60 | 4.52 | |
|
| ||||||||||
| GSES (self-efficacy) | NF | 23.78 | 5.43 | 27.61 | 5.09 | 3.83 | −3.239 |
| 1.34 | 6.33 |
| R | 30.15 | 5.76 | 28.69 | 6.16 | 1.46 | 1.000 | 0.327 | −1.55 | 4.47 | |
|
| ||||||||||
| BDNF serum | NF | 44.78 | 10.69 | 55.50 | 10.76 | 10.72 | −6.185 |
| 7.06 | 14.38 |
| R | 50.16 | 11.38 | 52.96 | 10.70 | 2.80 | −1.575 | 0.128 | −6.47 | 0.87 | |
|
| ||||||||||
| QEEG C-z theta/beta | NF | 1.92 | 0.57 | 2.29 | 0.88 | 0.37 | −2.632 |
| 0.07 | 0.67 |
| R | 2.35 | 0.94 | 2.49 | 0.82 | 0.14 | −1.453 | 0.159 | −0.34 | 0.06 | |
|
| ||||||||||
| QEEG F-z theta/SMR | NF | 2.07 | 0.64 | 2.37 | 0.80 | 0.30 | −2.358 |
| 0.03 | 0.57 |
| R | 2.49 | 1.00 | 2.60 | 0.83 | 0.10 | −1.013 | 0.321 | −0.31 | 0.10 | |
|
| ||||||||||
| F-z N1 (amplitude) | NF | −3.95 | 2.53 | −5.36 | 1.93 | 1.41 | 2.588 |
| −2.57 | −0.26 |
| R | −5.29 | 3.93 | −6.58 | 3.44 | 1.30 | 1.263 | 0.219 | −0.83 | 3.42 | |
|
| ||||||||||
| C-z P2 (latency) | NF | 208.82 | 14.81 | 196.06 | 18.27 | 12.77 | 2.643 |
| −23.01 | −2.52 |
| R | 203.92 | 23.94 | 205.04 | 21.70 | 1.13 | −0.185 | 0.855 | −13.68 | 11.43 | |
M: mean value; SD: standard deviation; CV%: coefficient of variation; T: Student's t-test; P: level of significance; PANSS-POS: Positive and Negative Syndrome Scale-Positive; PANSS-NEG: Positive and Negative Syndrome Scale-Negative; PANSS-GEN: Positive and Negative Syndrome Scale-General; PANSS-TOT: Positive and Negative Syndrome Scale-Total; BDNF: brain-derived neurotrophic factor; BCIS: Beck Cognitive Insight Scale; AIS: Acceptance of Illness Scale; GSES: General Self-Efficacy Scale; QEEG C-z theta/beta: attention factor of the central area; QEEG F-z theta/SMR: concentration factor of the central area; F-z N1 (amplitude): amplitude of the first negative component of the central area; C-z P2 (latency): delay of the second positive component of the central area.
Primary outcomes: statistically significant differences between groups R and NF in the magnitude of change from pre- to posttherapy outcomes.
| Variable (change between measurements for the variable) | Group R | Group NF | In-between comparisons | |||
|---|---|---|---|---|---|---|
| M | SD | M | SD |
| ||
| BDNF (neurotrophic factor) | 2.80 | 8.89 | 10.72 | 7.35 | −3.093A | 0.004 |
| GSES (self-efficacy) | −1.46 | 7.45 | 3.83 | 5.02 | 119.5B | 0.005 |
M: mean; SD: standard deviation; A: Student's t-test; B: Mann-Whitney U test; P: statistical significance.
Correlations between the magnitude of changes from pretherapy to posttherapy measurements in the group of patients following a standard rehabilitation program (group R).
| Variable | Group R (standard rehabilitation program) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| PANSS-POS | PANSS-NEG | PANSS-GEN | PANSS-TOT | BDNF (ng/ml) | QEEG theta/beta | QEEG theta/SMR | N1 amplitude | P2 latency | |
| PANSS-POS |
|
|
|
|
|
|
|
| − |
| PANSS-NEG |
|
|
|
| − |
|
| − | − |
| PANSS-GEN |
|
|
|
| − |
|
|
| − |
| PANSS-TOT |
|
|
|
| − |
|
|
| − |
| BDNF (ng/ml) | − | − | − | − | — | 0.101 | 0.140 | 0.433 | −0.117 |
| QEEG theta/beta |
|
|
|
| 0.101 | — | 0.904∗ | 0.007 | −0.498∗ |
| QEEG theta/SMR |
|
|
|
| 0.14 | 0.904∗ | — | 0.181 | −0.488∗ |
| N1 (amplitude) |
| − |
|
| 0.433 | 0.007 | 0.181 | — | −0.555∗ |
| P2 (latency) | − | − | − | − | −0.117 | −0.498∗ | −0.488∗ | −0.555∗ | — |
Correlations were assessed using Spearman's rank correlation coefficients (italics) and Pearson's r; statistically significant correlations (P < 0.050) are marked with an asterisk (∗).
Correlations between the magnitudes of changes from pretherapy to posttherapy measurements in the group of patients participating in a combined NF/standard rehabilitation program (group NF).
| Variable | Group NF (combined NF/standard rehabilitation) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| PANSS-POS | PANSS-NEG | PANSS-GEN | PANSS-TOT | BDNF (ng/ml) | QEEG theta/beta | QEEG theta/SMR | N1 amplitude | P2 latency | |
| PANSS-POS |
|
|
|
| − |
|
| − |
|
| PANSS-NEG |
|
|
|
| − |
|
| − | − |
| PANSS-GEN |
|
|
|
| − |
|
| − |
|
| PANSS-TOT |
|
|
|
| − |
|
| − |
|
| BDNF (ng/ml) | − | − | − | − | — | 0.123 | 0.057 | 0.153 | 0.296 |
| QEEG theta/beta |
|
|
|
| 0.123 | — | 0.875∗ | −0.161 | −0.127 |
| QEEG theta/SMR |
|
|
|
| 0.057 | 0.875∗ | — | −0.298 | −0.297 |
| N1 (amplitude) | − | − | − | − | 0.153 | −0.161 | −0.298 | — | 0.035 |
| P2 (latency) |
| − |
|
| 0.296 | −0.127 | −0.297 | 0.035 | — |
Correlations were assessed using Spearman's rank correlation coefficients (italics) and Pearson's r; statistically significant correlations (P < 0.050) are marked with an asterisk (∗).